23rd CardioVascular Summit -TCTAP 2018 Seoul, Korea, April 28 - May 1, 2018

## EVT Guidelines: What has been changed? Carotid Artery Stenosis: Optimal Candidate for Revascularization

Horst Sievert,

Ilona Hofmann, Laura Vaskelyte, Sameer Gafoor, Stefan Bertog, Predrag Matić, Markus Reinartz,

Bojan Jovanovic, Kolja Sievert, Iris Grunwald, Nalan Schnelle

CardioVascular Center Frankfurt - CVC,

Frankfurt, Germany

## Disclosures

Physician name Horst Sievert

Company

4tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Cibiem, CGuard, Comed B.V., Contego, CVRx, Edwards, Endologix, Hemoteq, InspireMD, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, pfm Medical, Recor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, Vivasure Medical, Venus, Veryan

Relationship Consulting fees, Travel expenses, Study honoraria

#### 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)



Endorsed by the European Stroke Organization (ESO)

The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) **ESC Chairperson:** Victor Aboyans (France). **Co-Chairperson:** Jean-Baptiste Ricco<sup>1</sup> (France).

Authors/Task Force Members: Marie-Louise EL Bartelink (The Netherlands), Martin Björck<sup>1</sup> (Sweden), Marianne Brodmann (Austria), Tina Cohnert<sup>1</sup> (Austria), Jean-Philippe Collet (France), Martin Czerny (Germany), Marco De Carlo (Italy), Sebastian Debus<sup>1</sup> (Germany), Christine Espinola-Klein (Germany), Thomas Kahan (Sweden), Serge Kownator (France), Lucia Mazzolai (Switzerland), A. Ross Naylor<sup>1</sup> (UK), Marco Roffi (Switzerland), Joachim Röther<sup>2</sup> (Germany), Muriel Sprynger (Belgium), Michal Tendera (Poland), Gunnar Tepe (Germany), Maarit Venermo<sup>1</sup> (Finland), Charalambos Vlachopoulos (Greece), Ileana Desormais (France).


Document Reviewers: Petr Widimsky (ESC Review Coordinator) (Czech Republic), Philippe Kolh (ESVS Review Coordinator) (Belgium), Stefan Agewall (Norway), Héctor Bueno (Spain), Antonio Coca (Spain), Gert J. De Borst<sup>1</sup> (The Netherlands), Victoria Delgado (The Netherlands), Florian Dick<sup>1</sup> (Switzerland), Cetin Erol (Turkey), Marc Ferrini (France), Stavros Kakkos<sup>1</sup> (Greece/UK), Hugo A. Katus (Germany), Juhani Knuuti (Finland), Jes Lindholt<sup>1</sup> (Denmark), Heinrich Mattle<sup>2</sup> (Switzerland), Piotr Pieniazek (Poland), Massimo Francesco Piepoli (Italy), Dierk Scheinert (Germany), Horst Sievert (Germany), Iain Simpson (UK), Jakub Sulzenko (Czech Republic), Juan Tamargo (Spain), Lale Tokgozoglu (Turkey), Adam Torbicki (Poland), Nikolaos Tsakountakis (Greece), José Tuñón (Spain), Melina Vega de Ceniga<sup>1</sup> (Spain), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain).

# A very difficult topic for me!

- I was involved in the development of these guidelines over the last decade
- As you can imagine, with so many others involved, I could not always prevail
- Guidelines are always a compromise
  - Honestly, I prefer to convince rather than to compromise
- Also, I always try **not** to follow the guidelines
  - But instead to be ahead of them

#### What has changed in 2017?

Change in recommendations						
2011						
Carotid	Artery Disease					
EPDs in	carotid stenting					
Asymptomatic	60-99% carotid stenosis					
Surgery for all     Surgery for high stroke risk						
. Ctanting as an alternative	<ul> <li>Stenting in high surgery risk</li> </ul>					
<ul> <li>Stenting as an alternative</li> </ul>	<ul> <li>Stenting in average surgical risk</li> </ul>					



#### What is new?





#### **New/revised concept**


Risk stratification for asymptomatic carotid disease.

# Imaging

Recommendations	Class	Level
DUS (as first-line), CTA and/or MRA are recommended for evaluating the extent and severity of extracranial carotid stenoses.	ŀ	В
When CAS is being considered, it is recommended that any DUS study be followed either by MRA or CTA to evaluate the aortic arch, as well as the extra- and intracranial circulation.	I	В
When CEA is considered, it is recommended that the DUS stenosis estimation be corroborated either by <u>MRA or CTA</u> (or by a repeat DUS study performed in an expert vascular laboratory).	ľ	В

## Asymptomatic carotid stenoses

# After the initial negative randomized trials carotid surgery was finally established in the 1990s by these trials:



# These trials comparing CEA with medical therapy are considered to be outdated

I could give another 10 min lecture explaining why I have some doubts

Features associated with increased risk of stroke in patients with asymptomatic carotid stenosis treated medically

Clinicalª	Contralateral TIA/stroke <sup>121</sup>
Cerebral imaging	• Ipsilateral silent infarction <sup>122</sup>
Ultrasound imaging	<ul> <li>Stenosis progression (&gt; 20%)<sup>123</sup></li> <li>Spontaneous embolization on transcranial Doppler (HITS)<sup>124</sup></li> <li>Impaired cerebral vascular reserve<sup>125</sup></li> <li>Large plaques<sup>b126</sup></li> <li>Echolucent plaques<sup>96</sup></li> <li>Increased juxta-luminal black (hypoechogenic) area<sup>127</sup></li> </ul>
MRA	<ul> <li>Intraplaque haemorrhage<sup>128</sup></li> <li>Lipid-rich necrotic core</li> </ul>

HITS = high intensity transient signal; MRA = magnetic resonance angiography; TIA = transient ischaemic attack.

<sup>a</sup>Age is not a predictor of poorer outcome.

<sup>b</sup>More than 40 mm<sup>2</sup> on digital analysis.

#### Management of asymptomatic carotid stenoses

Recommendations	Class	Level
In "average surgical risk" patients with an asymptomatic 60-99% stenosis, CEA should be considered in the presence of clinical and/or more imaging characteristics that may be associated with an increased risk of late ipsilateral stroke, provided documented perioperative stroke/death rates are <3% and the patient's life expectancy is >5 years.		В
In asymptomatic patients who have been deemed "high-risk for CEA" and who have an asymptomatic 60-99% stenosis in the presence of clinical and/or imaging characteristics that may be associated with an increased risk of late ipsilateral stroke, CAS should be considered, provided documented perioperative stroke/death rates are <3% and the patient's life expectancy is >5 years.	lla	B
In <b>"average surgical risk"</b> patients with an asymptomatic <b>60-99%</b> stenosis in the presence of clinical and/or imaging characteristics <sup>d</sup> that may be associated with an increased risk of late ipsilateral stroke, <b>CAS may be an alternative to CEA</b> provided documented perioperative stroke/death rates are <3% and the patient's life expectancy is >5 years.		В

#### Management of asymptomatic carotid stenoses


#### • Treatment only if

- degree of stenosis is 60-99%
- If there are additional stroke risk factors (clinical, imaging)
- If risk of treatment in your center is <3%
- If life expectancy is > 5 yrs
- CAS in hight surgical risk patients
- Surgery in "average surgical risk" patients
  - but surgery may be considered


Management depends upon degree of stenosis Slightly different thresholds for symptomatic stenoses

Asymptomatic

**Symptomatic** 



#### Management of symptomatic stenoses



#### Management of symptomatic stenoses

Recommendations	Class	Level	
<b>CEA</b> is recommended in symptomatic patients with <b>70-99%</b> carotid stenoses, provided the documented procedural death/stroke rate is <6%.		A	
<b>CEA</b> should be considered in symptomatic patients with <b>50-69%</b> carotid stenoses, provided the documented procedural death/stroke rate is <6%.	lla	A	
In recently symptomatic patients with a <b>50–99%</b> stenosis who present with adverse anatomical features or medical comorbidities that are considered to make them "high-risk for CEA", <b>CAS</b> should be considered, provided the documented procedural death/stroke rate is <6%.	lla	В	

#### Management of symptomatic stenoses

Recommendations		Level
When revascularization is indicated in "average surgical risk" patients with symptomatic carotid disease, CAS may be considered as an alternative to surgery, provided the documented procedural death/ stroke rate is <6%.	IIb	B
When decided, it is recommended to perform revasculariz- ation of symptomatic 50–99% carotid stenoses as soon as possible, preferably within 14 days of symptom onset.	1	A
Revascularization is not recommended in patients with a <50% carotid stenosis.	ш	Α

#### **Embolic protection devices**

Recommendations		Level	
The use of embolic protection devices should be considered in patients undergoing carotid artery stenting.	lla	С	

#### Carotid stenoses in patients undergoing CABG

Recommendations		Class	Level	]					
In patients undergoing CABC patients with a recent (<6 m	G, DUS is recommended in nonths) history of TIA/stroke.	1	В						
In patients with no recent (<	< 6 months) history of TIA/stroke,								
DUS may be considered in t	Recommendations				Class	Level	]		
years, multivessel coronary LEAD, or carotid bruit.	It is recommended that the indication (and timing) for carotid revascularization be ind discussion within a multidisciplinary team,	ividuali	zed afte	er	1	С			
Screening for carotid stenos requiring urgent CABG with In patients scheduled for CABG, with rec • Carotid revascularization should be con			nonths)	history of 1		oke:			
	99% carotid stenosis,			Recommendat				Class	Level
	<ul> <li>Carotid revascularization with CEA should choice in patients with 50–99% carotid st</li> </ul>			• Routine p	rophylad	ctic caro	tic patients scheduled for CABG: tid revascularization in patients with	Ш	В
	Carotid revascularization is not recomme	nded in	patier				-		
	carotid stenosis <50%.		<ul> <li>Carotid revascularization may be considered in patients with bilateral 70-99% carotid stenoses or 70-99% carotid stenosis + contralateral occlusion.</li> </ul>		llb	В			
a 70- chara ipsilat		a 70–99% character	carotid istics that stroke,	stenosis at may b in order	may be considered in patients with s, in the presence of one or more e associated with an increased risk of to reduce stroke risk beyond the	lib	с		


#### Carotid stenoses in patients undergoing CABG

- Perform CEA or CAS if indicated anyway
- There is only one special indication:
  - CEA or CAS may be considered in asymptomatic bilateral high grade stenosis 70-99% or unilateral + contralateral occlusion (IIB, level B)
- Routine CEA or CAS should not be performed

#### As always ....

... guidelines are outdated at the time when they are published

We now have several prospective controlled clinical trials with proximal protection and a 30 day stroke rate < 3%



#### CVC Frankfurt:


# Stroke rate is even lower if you use proximal protection in **all** patients and not only in "high risk"

	@ discharge	@ 30 day FU
Death	0	0
Stroke	0	1 (0.8%)
TIA	0	0
Myocardial infarction	0	0


N = 124

Hornung M et al, EuroIntervention 2014

## Micro-mesh Stents



### CARENET trial (CGuardTM)



	Post Procedure	Discharge	30 days
Device success	100%	NA	NA
MACE	0%	0%	0%
Death	0%	0%	0%
MI	0%	0%	0%
Stroke	0%	0%	0%

SCHOFER J, MUSIALEK P, KOLVENBACH R, SIEVERT H: TCT 2014

#### Integrated Embolic Protection (IEP)<sup>™</sup> for post-dilatation

Angioplasty

Catheter

Balloon

Integrated Filter:

- 40 Micron pores
- Baseline closed
- Sheathless

 $\checkmark$  The first device that combines an embolic protection filter and balloon

✓ 40 micron pore size allows micro-embolic capture

✓ Filter size can be adjusted to suit each patient's unique anatomy



#### **PALADIN Registry**

Post-Procedural and % (N/105<sup>1</sup>) 30-Day Outcomes

Stroke, Death and MI0.95 % (1)Death0Stroke0.95 % (1)Myocardial Infarction0


**Stroke and Death** 

0.95 % (1)

<sup>1</sup> Of the 106 subjects enrolled, one (1) subject withdrew consent following discharge, and 105 were eligible for follow up at 30 days. This patient had no neurological events

- 106 patients
- Technical success 99%
- No Deaths, strokes, MI or other Major Adverse Events (MAE) through discharge
- 1 stroke at day 12 due to stent thrombosis of a mesh-covered stent

# Using PALADIN, clinical outcome was superior compared to almost all other carotid stenting studies




#### **Transcervical Carotid Artery Revascularization**



1-2cm Incision



- Local anesthesia
- Flow reversal circuit: carotid artery to femoral vein



#### **Transcervical Carotid Artery Revascularization**



#### **ROADSTER Trial 12-month Outcomes**

High Surgical Risk		roup, ITT 141)		iroup, PP 136)
S/D/MI*	5	3.5%	4	2.9%
Major Stroke	0	0%	0	0%
Minor Stroke	2	1.4%	1	0.7%
Death	2	1.4%	2	1.5%
MI	1	0.7%	1	0.7%
Stroke & Death	4	2.8%	3	2.2%
Cranial Nerve Injury (CNI)	1	0.7%	1	0.7%
CNI Unresolved at 6 Mos	0	0%	0	0%

# Summary

- According to the recent ESC guidelines, asymptomatic carotid stenoses should be treated by CEA or CAS only if there are defined additional clinical or morphologic risk factors for stroke
- Symptomatic stenoses > 50% should be treated as early as possible
  - CAS should be considered in high surgical risk patients
  - CEA should be considered in patients without high surgical risk but CAS can be considered
- More recent CAS technologies like proximal occlusion, flow reversal, double filtration and mesh-stents with stroke rates
  - < 1% are used now as a routine in many centers
    - But these have not been included in the 2017 guidelines
- The debate goes on

#### They have no idea ...



## ... what we are talking about

## Thank you!

# ICCA STROKE INTERVENTIONS & CAROTID STENTING



www.ICCAonline.org